Identification of Novel endpoints through the characterization of Early treated cohorts – Immunological Platform
During EPIICAL first phase, the Immunological working group described the peculiar characteristics of the immune response in perinatally infected children, who were treated early and have achieved a good control of the virus replication in the early phase of their life.
The aim of WG2 in EPIICAL 2020-2024 is to identify the specific immune profiling of children treated early. We will do this will by using innovative techniques, such as epigenetic studies, proteomics and transcriptomic studies, evaluation of HIV specific cellular and humoral immunity. These novel endpoints will contribute to the body of information for new immunotherapeutic strategies to be tested in children.
People: Paolo Palma; Savita Pahwa; Ofer Levy